Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
There is currently no study on the impact of biologic therapeutics on the microbiome, despite variable patients’ response to biologics used to treat gut-joint-axis diseases.
We studied microbiome variations resulting from different TNF-antagonist treatments in an in vivo mouse model.
We showed a dysbiosis of the microbiome after treatment in young mice, and identified major bacteria involved in TNF-antagonists exposure. These bacteria were different between males and females.
Keywords : Gut microbiome, TNF inhibitors, Dysbiosis
|☆|| Disclaimer: This manuscript reflects the views of the authors and should not be construed to represent FDA's views or policies.